Haleon plc purchased 1,569,800 ordinary shares for cancellation under its buyback programme on August 17 and 18, 2026. The company has now completed the £500 million share buyback programme originally announced on March 12, 2026. Since the start of the year, Haleon repurchased a total of 144,012,239 shares, all of which were cancelled. Following these transactions, the registered share capital stands at 8,808,341,409 ordinary shares, with 11,807,443 held as treasury shares and 8,796,533,966 carrying voting rights. Haleon plc operates in the consumer healthcare industry, manufacturing and selling over-the-counter medicines and health supplements under brands such as Advil, Panadol, and Sensodyne.

Haleon plc purchased a total of 10,995,213 ordinary shares for cancellation under its share buyback programme announced on 12 March 2026. Purchases occurred on August 11, 12, and 13, 2026, across multiple trading venues including the London Stock Exchange, CBOE (UK), Aquis, BXE, and CXE. Prices ranged from a low of 355.80 pence to a high of 367.00 pence per share. Following settlement, registered share capital stands at 8,809,911,209 shares, with 11,807,443 held as treasury shares and 8,798,103,766 carrying voting rights. Haleon plc operates in the consumer healthcare industry, manufacturing and selling over-the-counter medicines and health supplements under brands such as Advil, Panadol, and Sensodyne.

Haleon plc reported half-year results for the period ended June 30, 2026, with revenue increasing 2.2% to £5,602m and adjusted operating profit rising 8.2% to £1,364m at constant currency. The company declared an interim dividend of 2.4p per share, a 9% increase year-over-year, and completed £457m in share buybacks against its £500m annual allocation. Haleon maintained its FY 2026 guidance for organic revenue growth of 3-5% and high-single-digit adjusted operating profit growth. The company operates in the consumer health industry, manufacturing and selling over-the-counter medicines and personal care products.

As of 30 June 2026, Haleon plc has 8,820,906,422 issued ordinary shares of £0.01 each. After accounting for 12,006,714 treasury shares, the total number of ordinary shares with voting rights is 8,808,899,708. This figure serves as the denominator for calculating notifiable interests under FCA Disclosure Guidance and Transparency Rules. Haleon plc is a consumer healthcare company focused on oral health, vitamins, pain relief, and other wellness categories.